ライフサイエンスコーパス: oblimersen

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 mersen, and 47% (95% CI, 21% to 73%) without oblimersen.

2 ggested worse outcome for patients receiving oblimersen.

3 red intravenously for 3 days with or without oblimersen 3 mg/kg/d as a 7-day continuous intravenous i

4 he current clinical information available on oblimersen, a novel antisense approach targeting Bcl-2 i

5 e, bevacizumab, ZD6474, imatinib, gefitinib, oblimersen and aplidine have all entered clinical trial

6 at 1 year was 24% (95% CI, 12% to 40%) with oblimersen, and 47% (95% CI, 21% to 73%) without oblimer

7 f the Bcl-2 oncoprotein can be achieved with oblimersen (antisense molecule specific for Bcl-2).

8 platin and etoposide with (arm A) or without oblimersen (arm B) in 56 assessable patients with chemot

9 a and thrombocytopenia were increased in the oblimersen-dacarbazine group; however, there was no incr

10 achieved in 20 (17%) of 120 patients in the oblimersen group and eight (7%) of 121 patients in the c

11 Phase I and phase II studies using oblimersen in combination with conventional chemotherapy

12 l trials have shown single-agent activity of oblimersen in patients with chronic lymphocytic leukemia

13 rials will establish the clinical utility of oblimersen in patients with hematologic malignancies.

14 y agents, proapoptotic small molecules (e.g. oblimersen, obatoclax, and gossypol), antifols (e.g. pra

15 Plasma concentrations of oblimersen (parent drug) and its major metabolites were

16 A randomized trial of oblimersen plus fludarabine/cyclophosphamide (OBL-FC; n

17 seline serum LDH and treatment was observed; oblimersen significantly increased survival in patients

18 reated elderly AML patients by administering oblimersen sodium (G3139), an 18-mer phosphorothioate an

19 Oblimersen sodium has modest single-agent activity in he

20 Dosing with oblimersen sodium in patients with CLL is limited by dev

21 ng Bcl-2 using an antisense oligonucleotide (oblimersen sodium) could improve the efficacy of systemi

22 Bcl-2 suppression by G3139 (oblimersen sodium), a phosphorothioate oligonucleotide c

23 s such as bortezomib, perifosine, atacicept, oblimersen sodium, and tositumomab show promise as ratio

24 cl-2 in chemoresistance in SCLC, addition of oblimersen to a standard regimen for this disease did no

25 The addition of oblimersen to dacarbazine significantly improved multipl

26 patients randomly assigned, the addition of oblimersen to dacarbazine yielded a trend toward improve

27 The addition of oblimersen to fludarabine plus cyclophosphamide signific

28 Oblimersen was administered at doses ranging from 3 to 7

29 ients who remained sensitive to fludarabine, oblimersen was associated with a four-fold increase in t

30 Oblimersen was associated with slightly more grade 3 to

31 Oblimersen was frequently associated with thrombocytopen

32 We evaluated whether oblimersen would improve response to chemotherapy in pat

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。